| Dr Malissa Gobbell Talbert, MD | |
|
1100 E 3rd St, Utfp, Chattanooga, TN 37403-2241 | |
| (423) 778-8837 | |
| Not Available |
| Full Name | Dr Malissa Gobbell Talbert |
|---|---|
| Gender | Female |
| Speciality | Geriatric Medicine |
| Experience | 36 Years |
| Location | 1100 E 3rd St, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497957914 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0300X | Internal Medicine - Geriatric Medicine | 20014 (Tennessee) | Primary |
| 207RR0500X | Internal Medicine - Rheumatology | 20014 (Tennessee) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health Chattanooga | Chattanooga, TN | Home health agency |
| Erlanger Medical Center | Chattanooga, TN | Hospital |
| Alexian Village Of Tennessee | Signal mountain, TN | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Erlanger Health | 1153780226 | 352 |
News Archive
The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.
Discovery of a novel, advanced technique to identify the rare cells where human immunodeficiency virus (HIV) hides in patients taking antiretroviral therapy (ART). This is an important step forward in the search for a HIV/AIDS cure.
Results from the U.S. registry of Abiomed, Inc. AB5000 patients were recently published in the September 2010 issue of The Annals of Thoracic Surgery. The paper, "Use of the AB5000TM Ventricular Assist Device in Cardiogenic Shock After Acute Myocardial Infarction (AMI)," concludes that the "results from this nationwide registry suggest that VADs can restore normal hemodynamics and support recovery of native cardiac function in the majority of survivors when conventional therapies fail."
Buprenorphine (BUP) is approved for the treatment of opioid addiction. The current dosing regimen of BUP in pregnant women is based on recommendations designed for non-pregnant adults, but physiological changes during pregnancy may alter BUP exposure and efficacy.
› Verified 3 days ago
| Entity Name | Chattanooga Hamilton County Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154751931 PECOS PAC ID: 0547179731 Enrollment ID: O20040302001086 |
News Archive
The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.
Discovery of a novel, advanced technique to identify the rare cells where human immunodeficiency virus (HIV) hides in patients taking antiretroviral therapy (ART). This is an important step forward in the search for a HIV/AIDS cure.
Results from the U.S. registry of Abiomed, Inc. AB5000 patients were recently published in the September 2010 issue of The Annals of Thoracic Surgery. The paper, "Use of the AB5000TM Ventricular Assist Device in Cardiogenic Shock After Acute Myocardial Infarction (AMI)," concludes that the "results from this nationwide registry suggest that VADs can restore normal hemodynamics and support recovery of native cardiac function in the majority of survivors when conventional therapies fail."
Buprenorphine (BUP) is approved for the treatment of opioid addiction. The current dosing regimen of BUP in pregnant women is based on recommendations designed for non-pregnant adults, but physiological changes during pregnancy may alter BUP exposure and efficacy.
› Verified 3 days ago
| Entity Name | Erlanger Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477256303 PECOS PAC ID: 1153780226 Enrollment ID: O20230707000849 |
News Archive
The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.
Discovery of a novel, advanced technique to identify the rare cells where human immunodeficiency virus (HIV) hides in patients taking antiretroviral therapy (ART). This is an important step forward in the search for a HIV/AIDS cure.
Results from the U.S. registry of Abiomed, Inc. AB5000 patients were recently published in the September 2010 issue of The Annals of Thoracic Surgery. The paper, "Use of the AB5000TM Ventricular Assist Device in Cardiogenic Shock After Acute Myocardial Infarction (AMI)," concludes that the "results from this nationwide registry suggest that VADs can restore normal hemodynamics and support recovery of native cardiac function in the majority of survivors when conventional therapies fail."
Buprenorphine (BUP) is approved for the treatment of opioid addiction. The current dosing regimen of BUP in pregnant women is based on recommendations designed for non-pregnant adults, but physiological changes during pregnancy may alter BUP exposure and efficacy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Malissa Gobbell Talbert, MD 1100 E 3rd St, Utfp, Chattanooga, TN 37403-2241 Ph: (423) 778-8837 | Dr Malissa Gobbell Talbert, MD 1100 E 3rd St, Utfp, Chattanooga, TN 37403-2241 Ph: (423) 778-8837 |
News Archive
The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.
Discovery of a novel, advanced technique to identify the rare cells where human immunodeficiency virus (HIV) hides in patients taking antiretroviral therapy (ART). This is an important step forward in the search for a HIV/AIDS cure.
Results from the U.S. registry of Abiomed, Inc. AB5000 patients were recently published in the September 2010 issue of The Annals of Thoracic Surgery. The paper, "Use of the AB5000TM Ventricular Assist Device in Cardiogenic Shock After Acute Myocardial Infarction (AMI)," concludes that the "results from this nationwide registry suggest that VADs can restore normal hemodynamics and support recovery of native cardiac function in the majority of survivors when conventional therapies fail."
Buprenorphine (BUP) is approved for the treatment of opioid addiction. The current dosing regimen of BUP in pregnant women is based on recommendations designed for non-pregnant adults, but physiological changes during pregnancy may alter BUP exposure and efficacy.
› Verified 3 days ago
Dr. Pamela Rani Sud, MD Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 725 Glenwood Drive, Suite E-500, Chattanooga, TN 37404 Phone: 423-495-2635 Fax: 423-495-2638 | |
David Shved, D.O. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-5179 Fax: 423-778-2108 | |
Megan J Coylewright, M.D. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-8258 | |
Dr. Charles Robert Bosshardt, M.D. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 2515 Desales Ave Ste 206, Chattanooga, TN 37404 Phone: 423-698-8101 Fax: 423-698-3450 | |
Dr. Elise Helene Marshall, DO Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 605 Glenwood Dr Ste 300, Chattanooga, TN 37404 Phone: 423-495-2690 Fax: 423-495-2698 | |
Dr. Joshua Warner Hornsby, M.D. Geriatric Medicine Medicare: Medicare Enrolled Practice Location: 979 E 3rd St Ste A-440, Chattanooga, TN 37403 Phone: 423-778-2867 Fax: 423-778-2866 | |
Dr. Donald Franklin Mackler, MD Geriatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 721 Glenwood Dr, Ste. W552, Chattanooga, TN 37404 Phone: 423-629-6258 Fax: 423-629-9531 |